Differential tenofovir alafenamide (TAF) adoption in HBV-infected populations; assessment of care in US clinical practice Curry, M., Bae, H., Dieterich, D., Ankoma-Sey, V., Reddy, R., Pan, C., Hann, H., Tong, M., Kim, W., Kwo, P., Frazier, L., Cox, K., Milligan, S., Afdhal, N. ELSEVIER. 2020: S876

View details for Web of Science ID 000786587002525